var data={"title":"Ovine polyvalent crotalidae North and South American snake antivenom: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ovine polyvalent crotalidae North and South American snake antivenom: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/365571?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-drug-information\" class=\"drug drug_general\">see &quot;Ovine polyvalent crotalidae North and South American snake antivenom: Drug information&quot;</a> and <a href=\"topic.htm?path=ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ovine polyvalent crotalidae North and South American snake antivenom: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6516314\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>CroFab</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046640\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antivenin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046633\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-drug-information\" class=\"drug drug_general\">see &quot;Ovine polyvalent crotalidae North and South American snake antivenom: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Crotalid envenomation:</b> Children and Adolescents: Clinical trials included patients as young as 11 years of age. Use has been reported to be both safe and effective in children as young as 1 year of age (Johnson 2008; Schmidt 2005; Seifert 2009). <b>Note:</b> Antivenom dosage is based on venom load and severity of symptoms and not on patient size; therefore, a reduced, weight-based antivenom dose in pediatric patients is <b>not</b> recommended (Behm 2003; Lavonas 2011a; Offerman 2002). Clinicians are encouraged to contact their local poison control center or clinical toxicologist for consultation when treating any envenomed patient, but especially pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial dose: IV: 4 to 6 vials as soon as possible and preferably within 6 hours of snakebite; monitor for 1 hour following infusion to determine if initial control has been achieved as evidenced by arrest of local signs of envenomation (eg, leading edge of local injury is not progressing). Some clinicians recommend an initial dose of 8 to 12 vials in patients presenting with immediately life-threatening effects (eg, shock, respiratory distress, cardiovascular collapse, significant hemorrhage, or severe neurologic toxicity) (Goto 2009; Lavonas 2011a). If control is not achieved, repeat with additional dose of 4 to 6 vials until initial control is achieved and local manifestations, coagulation tests and systemic signs are normal. Maximum initial dose: 12 vials.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance dose (begin once control of envenomation achieved): IV: 2 vials every 6 hours for up to 18 hours. Optimal dosing beyond 18 hours has not been established; however, treatment may be continued if deemed necessary based on patient condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Crotalid envenomation:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial dose: 4 to 6 vials; treatment should begin as soon as possible and preferably within 6 hours of envenomation. Monitor for 1 hour following the infusion to determine if initial control has been achieved as evidenced by the arrest of local signs of envenomation (eg, leading edge of local injury is not progressing). Some clinicians recommend an initial dose of 8 to 12 vials for patients who present with immediately life-threatening effects (eg, shock, serious active bleeding) (Lavonas 2011). Repeat with an additional 4 to 6 vials if control is not achieved with the initial dose. Continue to treat with 4- to 6-vial doses until local manifestations, coagulation tests, and systemic signs are normal. Maximum initial dose: 12 vials.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance dose: Once control is achieved, administer 2 vials every 6 hours for up to 18 hours. Optimal dosing beyond 18 hours has not been established; however, treatment may be continued if deemed necessary based on the patient's condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6519242\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CroFab:  (1 ea) [contains thimerosal]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6516316\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046643\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV infusion: Administer at an initial rate of 25 to 50 mL/hour for the first 10 minutes; if tolerated and no allergic reaction observed, then increase rate so that total dose infuses over 60 minutes, usually to 250 mL/hour. Continue to monitor closely. Immediate treatment for anaphylactoid and/or hypersensitivity reactions should be available during the infusion. Decreasing the rate of infusion may help control some infusion-related adverse effects, such as fever, nausea, low back pain, and wheezing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6519214\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); excursions are permitted between -20&deg;C and 25&deg;C (-4&deg;F and 77&deg;F) for no longer than 7 days. Do not freeze. Use within 4 hours after reconstitution and dilution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046642\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Management of patients with North American crotalid envenomations [eg, rattlesnakes (<i>Crotalus</i>, <i>Sistrurus</i>), copperheads, and cottonmouth/water moccasins (<i>Agkistrodo</i>n)] [FDA approved in pediatric patients (age not specified) and adults]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6519437\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction, anaphylaxis, hypersensitivity reaction, serum sickness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma, cough, dyspnea, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Angioedema, blood coagulation disorder (delayed, recurrent), chest discomfort, delayed hypersensitivity, dizziness, erythema, headache, hemorrhage, hyperhidrosis, laryngeal edema, musculoskeletal chest pain, swelling of lips, swelling (recurrent and refractory to treatment), swollen tongue, tachycardia, tachypnea, thrombocytopenia (refractory to treatment), tremor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6515398\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to any component of the formulation (including papaya or papain), unless the benefits outweigh the risks and appropriate management for anaphylaxis is readily available</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6515399\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concern related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Derived from sheep plasma; anaphylaxis and anaphylactoid reactions are possible, especially in patients with known allergies to sheep protein. Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available prior to administration. In case of acute hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions, discontinue infusion and institute appropriate emergency treatment. Incidence of acute hypersensitivity reactions may be lower than previously thought (Buchanan 2009; Cannon 2008; Lavonas 2011). This product lacks the immunogenic Fc fragments and proteins found in the older equine-derived product. Sensitization may occur with repeated doses.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Processed with papain and may cause hypersensitivity reactions in patients allergic to papaya, other papaya extracts, papain, chymopapain, or the pineapple-enzyme bromelain. There may also be cross allergenicity with dust mite and latex allergens.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Crotalid envenomation: Should be used within 4 to 6 hours of the envenomation to prevent clinical deterioration and the development of coagulation abnormalities; however, the administration of antivenom may be beneficial even if treatment has been delayed (Bush 2013). Coagulation abnormalities are due directly to snake venom interference with the coagulation cascade. Recurrent coagulopathy occurs in approximately 50% of patients and may persist for 1 to 2 weeks or more; patients who have evidence of coagulopathy during the first 12 hours postantivenom treatment  have  an  ~66% chance of recurrence, which typically occurs 2 to 14 days after completion of antivenom administration (Boyer 2001). Repeat dosing may be indicated (Miller 2010; Ruha 2011). Patients should be monitored for at least 1 week and evaluated for other preexisting conditions associated with bleeding disorders. In severe envenomations, a decrease in platelets may occur, lasting hours to several days. Blood products are generally ineffective as they are rapidly consumed by circulating venom.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Product contains thimerosal with 0.03 mg of mercury per vial. Developing fetuses and young children may be at higher risk for mercury-related toxicities.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25855524\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Accumulation of thimerosal has been associated with neurological and renal toxicity; developing fetuses and young infants and children are most susceptible; the presence of thimerosal should not deter use as the risks of untreated crotalid envenomations far outweigh the risk of thimerosal exposure. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6519209\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=17062&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6516322\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Products contain thimerosal which may be associated with mercury-related toxicities, including neurological and renal toxicities in the fetus and very young children. In general, the health and prognosis of the mother should be taken into consideration when using medications as antidotes; they should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003). Experience with the use of antivenom in pregnancy is limited; however, treatment with antivenom should be considered in snake envenomations in which it is usually required as definitive management or in envenomations refractory to supportive care (Brown 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046639\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Vital signs; CBC, platelet count, prothrombin time, aPTT, fibrinogen levels, fibrin split products, clot retraction, bleeding and coagulation times, BUN, electrolytes, bilirubin; size of bite area (repeat every 15 to 30 minutes); intake and output; signs and symptoms of anaphylaxis/allergy; signs and symptoms of delayed allergic reaction or serum sickness (rash, fever, myalgia, arthralgia). CBC, platelet counts, and clotting studies should be evaluated at 6-hour intervals until patient is stable.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6519216\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A venom-specific fragment of IgG, which binds and neutralizes venom toxin, helping to remove the toxin from the target tissue and eliminate it from the body.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6519218\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Stability of patient or reduction in symptoms may be seen within 1 hour of administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Unbound Fab: 110 mL/kg (Seifert 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 12-23 hours (based on limited data)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Excretion of the venom:antibody complex is speculated to occur via the reticuloendothelial system (Dart  1997)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Unbound Fab: 5.9 mL/h/kg (Seifert 2001)</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Behm MO and Kearns GL, &quot;Crotaline Fab Antivenom for Treatment of Children With Rattlesnake Envenomation,&quot; <i>Pediatrics</i>, 2003, 112(6 Pt 1):1458&ndash;9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/14654633/pubmed\" target=\"_blank\" id=\"14654633\">14654633</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boyer LV, Seifert SA, and Cain JS, &ldquo;Recurrence Phenomena After Immunoglobulin Therapy for Snake Envenomations: Part 2. Guidelines for Clinical Management With Crotaline Fab Antivenom,&quot; Ann Emerg Med, 2001, 37(2):196-201.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/11174239/pubmed\" target=\"_blank\" id=\"11174239\">11174239</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brown SA, Seifert SA, Rayburn WF. Management of envenomations during pregnancy. <i>Clin Toxicol (Phila)</i>. 2013;51(1):3-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/23298218/pubmed\" target=\"_blank\" id=\"23298218\">23298218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buchanan JA, Varney SM, Mlynarchek SL, et al, &quot;Immediate Adverse Events (AEs) After Administration of Crotalidae Polyvalent Immune Fab (Fav AV),&quot; <i>Clin Toxicol</i>, 2009, 47(7):703.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bush SP, Seifert SA, Oakes J, et al. Continuous IV Crotalidae Polyvalent Immune Fab (Ovine) (FabAV) for selected North American rattlesnake bite patients. <i>Toxicon</i>. 2013;69:29-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/23474267/pubmed\" target=\"_blank\" id=\"23474267\">23474267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cannon R, Ruha AM, and Kashani J, &quot;Acute Hypersensitivity Reactions Associated With Administration of Crotalidae Polyvalent Immune Fab Antivenom,&quot; <i>Ann Emerg Med</i>, 2008, 51(4):407-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/18191286/pubmed\" target=\"_blank\" id=\"18191286\">18191286</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark RF, Williams SR, Nordt SP, Boyer-Hassen LV. Successful treatment of crotalid-induced neurotoxicity with a new polyspecific crotalid Fabantivenom. <i>Ann Emerg Med</i>. 1997;30(1):54-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/9209226/pubmed\" target=\"_blank\" id=\"9209226\">9209226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    CroFab (Crotalidae polyvalent immune Fab, ovine) [prescribing information]. West Conshohocken, PA: BTG International; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dart RC, Seifert SA, Carroll L, et al, &quot;Affinity-Purified, Mixed Monospecific Crotalid Antivenom Ovine Fab for the Treatment of Crotalid Venom Poisoning,&quot; <i>Ann Emerg Med</i>, 1997, 30(1):33-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/9209222/pubmed\" target=\"_blank\" id=\"9209222\">9209222</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goto CS and Feng SY, &quot;Crotalidae Polyvalent Immune Fab for the Treatment of Pediatric Crotaline Envenomation,&quot; <i>Pediatr Emer Care</i> 2009, 25(4):273-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/19369845/pubmed\" target=\"_blank\" id=\"19369845\">19369845</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson PN, McGoodwin L, and Banner W Jr, &quot;Utilisation of Crotalidae Polyvalent Immune Fab (Ovine) for Viperidae Envenomations in Children,&quot; <i>Emerg Med J</i>, 2008, 25(12):793-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/19033492/pubmed\" target=\"_blank\" id=\"19033492\">19033492</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keating GM. Crotalidae polyvalent immune Fab: in patients with North American crotaline envenomation. <i>BioDrugs</i>. 2011;25(2):69-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/21443271/pubmed\" target=\"_blank\" id=\"21443271\">21443271</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lavonas EJ, Kokko J, Schaeffer TH, et al, &ldquo;Short-Term Outcomes After Fab Antivenom Therapy for Severe Crotaline Snakebite,&rdquo; <i>Ann Emerg Med</i>, 2011, 579(2):128-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/20952098/pubmed\" target=\"_blank\" id=\"20952098\">20952098</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lavonas EJ, Ruha AM, Banner W, et al, &quot;Unified Treatment Algorithm for the Management of Crotaline Snakebite in the United States: Results of an Evidence-Informed Consensus Workshop,&quot; <i>BMC Emerg Med</i>, 2011a, 11:2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/21291549/pubmed\" target=\"_blank\" id=\"21291549\">21291549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lynch MJ, Ritter SC, Cannon RD. Successful treatment of South American rattlesnake (Crotalus durissus terrificus) envenomation with Crotalidae polyvalent immune Fab (CroFab&trade;). <i>J Med Toxicol</i>. 2011;7(1):44-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/20658221/pubmed\" target=\"_blank\" id=\"20658221\">20658221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller AD, Young MC, DeMott MC, et al, &quot;Recurrent Coagulopathy and Thrombocytopenia in Children Treated With Crotalidae Polyvalent Immune Fab: A Case Series,&quot; <i>Pediatr Emerg Care</i>, 2010, 26(8):576-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/20693856/pubmed\" target=\"_blank\" id=\"20693856\">20693856</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Offerman SR, Bush SP, Moynihan JA, et al, &quot;Crotaline Fab Antivenom for the Treatment of Children With Rattlesnake Envenomation,&quot; <i>Pediatrics</i>, 2002, 110(5):968-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/1241503/pubmed\" target=\"_blank\" id=\"1241503\">1241503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pizon AF, Riley BD, LoVecchio F, et al, &quot;Safety and Efficacy of Crotalidae Polyvalent Immune Fab in Pediatric Crotaline Envenomations,&quot; <i>Acad Emerg Med</i>, 2007, 14(4):373-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/17296804/pubmed\" target=\"_blank\" id=\"17296804\">17296804</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quan AN, Quan D, and Curry SC, &ldquo;Improving Crotalidae Polyvalent Immune Fab Reconstitution Times,&rdquo; <i>Am J Emerg Med</i>, 2010, 28(5):593-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/20579555/pubmed\" target=\"_blank\" id=\"20579555\">20579555</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruha AM, Curry SC, Albrecht C, et al, &quot;Late Hematologic Toxicity Following Treatment of Rattlesnake Envenomation With Crotalidae Polyvalent Immune Fab Antivenom,&quot; <i>Toxicon</i>, 2011, 57(1):53-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/20920516/pubmed\" target=\"_blank\" id=\"20920516\">20920516</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schmidt JM. Antivenom therapy for snakebites in children: is there evidence? <i>Curr Opin Pediatr</i>. 2005;17(2):234-238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/15800419/pubmed\" target=\"_blank\" id=\"15800419\">15800419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seifert SA, Boyer LV, Benson BE, Rogers JJ. AAPCC database characterization of native U.S. venomous snake exposures, 2001-2005. <i>Clin Toxicol (Phila)</i>. 2009;47(4):327-335.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/19514880/pubmed\" target=\"_blank\" id=\"19514880\">19514880</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seifert SA, Boyer LV, Dart RC, Porter RS, Sjostrom L. Relationship of venom effects to venom antigen and antivenom serum concentrations in a patient with Crotalus atrox envenomation treated with a Fab antivenom. <i>Ann Emerg Med</i>. 1997;30(1):49-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/9209225/pubmed\" target=\"_blank\" id=\"9209225\">9209225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seifert SA, Boyer LV. Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies. <i>Ann Emerg Med. </i>2001; 37(2):189-195.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/11174238/pubmed\" target=\"_blank\" id=\"11174238\">11174238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yin S, Kokko J, Lavonas E, Mlynarchek S, Bogdan G, Schaeffer T. Factors associated with difficulty achieving initial control with crotalidae polyvalent immune fabantivenom in snakebite patients. <i>Acad Emerg Med</i>. 2011;18(1):46-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/21166732/pubmed\" target=\"_blank\" id=\"21166732\">21166732</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 17062 Version 46.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F6516314\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1046640\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1046633\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F6519242\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F6516316\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1046643\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F6519214\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1046642\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F6519437\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F6515398\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F6515399\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25855524\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6519209\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6516322\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1046639\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F6519216\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F6519218\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/17062|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-drug-information\" class=\"drug drug_general\">Ovine polyvalent crotalidae North and South American snake antivenom: Drug information</a></li><li><a href=\"topic.htm?path=ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-patient-drug-information\" class=\"drug drug_patient\">Ovine polyvalent crotalidae North and South American snake antivenom: Patient drug information</a></li></ul></div></div>","javascript":null}